{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:26:14Z","timestamp":1780471574603,"version":"3.54.1"},"reference-count":94,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.autrev.2010.05.017","type":"journal-article","created":{"date-parts":[[2010,5,27]],"date-time":"2010-05-27T14:01:39Z","timestamp":1274968899000},"page":"674-683","source":"Crossref","is-referenced-by-count":79,"title":["Current therapeutic approaches to autoimmune chronic uveitis in children"],"prefix":"10.1016","volume":"9","author":[{"given":"Gabriele","family":"Simonini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Bresci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Galeazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Cimaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2010.05.017_bib1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.autrev.2008.07.034","article-title":"Clinical and genetic aspects of Blau syndrome: a 25-year follow-up of one family and a literature review","volume":"8","author":"Punzi","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2010.05.017_bib2","doi-asserted-by":"crossref","first-page":"A325","DOI":"10.1016\/j.autrev.2009.11.012","article-title":"Geoepidemiology: the environment and spondyloarthropathies","volume":"9","author":"Ehrenfeld","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2010.05.017_bib3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1517\/14728220902852570","article-title":"Recent developments in the treatment of uveitis: an update","volume":"18","author":"Lyon","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.autrev.2010.05.017_bib4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/IIO.0b013e31817d7107","article-title":"Therapy of uveitis in children","volume":"48","author":"Zierhut","year":"2008","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.autrev.2010.05.017_bib5","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archopht.126.9.1191","article-title":"Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results","volume":"126","author":"Callanan","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/0301-4738.58466","article-title":"Treatment of uveitis: beyond steroids","volume":"58","author":"Sangwan","year":"2010","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0022-3476(98)70232-X","article-title":"Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis","volume":"133","author":"Weiss","year":"1998","journal-title":"J Pediatr"},{"key":"10.1016\/j.autrev.2010.05.017_bib8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/09273940590951061","article-title":"Outcomes of treatment with immunomodulatory therapy in patients with corticosteroid-resistant juvenile idiopathic arthritis-associated chronic iridocyclitis","volume":"13","author":"Yu","year":"2005","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.autrev.2010.05.017_bib9","first-page":"362","article-title":"Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis","volume":"32","author":"Foeldvari","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2010.05.017_bib10","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/112067210701700509","article-title":"Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication","volume":"17","author":"Heiligenhaus","year":"2007","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib11","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib12","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/ard.47.12.988","article-title":"Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20year follow-up study","volume":"47","author":"Silman","year":"1988","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2010.05.017_bib13","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ajo.2009.05.008","article-title":"Azathioprine for ocular inflammatory diseases","volume":"148","author":"Pasadhika","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3928\/01913913-20070101-03","article-title":"Immunosuppressants used in a steroid-sparing strategy for childhood uveitis","volume":"44","author":"Schatz","year":"2007","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.autrev.2010.05.017_bib15","first-page":"61","article-title":"Pars planitis in the Mexican Mestizo population: ocular findings, treatment, and visual outcome","volume":"2","author":"Arellanes-Garc\u0131a","year":"2003","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.autrev.2010.05.017_bib16","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1515\/CCLM.2000.191","article-title":"Pharmacodynamic monitoring of mycophenolate mofetil","volume":"38","author":"Budde","year":"2000","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.autrev.2010.05.017_bib17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1034\/j.1399-3046.2001.005002112.x","article-title":"Mycophenolatemofetil in pediatric heart transplant recipients: a single-center experience","volume":"5","author":"Dipchand","year":"2001","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.autrev.2010.05.017_bib18","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0161-6420(03)00092-7","article-title":"Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders","volume":"110","author":"Baltatzis","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2010.05.017_bib19","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0161-6420(99)90078-7","article-title":"Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease","volume":"106","author":"Larkin","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2010.05.017_bib20","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.ophtha.2005.02.020","article-title":"Mycophenolate mofetil therapy for inflammatory eye disease","volume":"112","author":"Thorne","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2010.05.017_bib21","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ajo.2008.03.004","article-title":"Mycophenolate mofetil for treatment of uveitis","volume":"146","author":"Teoh","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib22","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bjo.2006.094698","article-title":"Mycophenolate mofetil in the treatment of uveitis in children","volume":"91","author":"Doycheva","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib23","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.ophtha.2007.12.011","article-title":"Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis","volume":"115","author":"Sobrin","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2010.05.017_bib24","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1517\/13543784.16.10.1525","article-title":"Next-generation calcineurin inhibitors for opthalmic indication","volume":"16","author":"Anglade","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.autrev.2010.05.017_bib25","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/0140-6736(91)92309-P","article-title":"Uveitis: pathogenesis","volume":"338","author":"Forrester","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2010.05.017_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/08830180212063","article-title":"Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis","volume":"21","author":"Caspi","year":"2002","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.autrev.2010.05.017_bib27","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0021-5155(97)00083-X","article-title":"Tacrolimus\u2013rapamycin combination therapy for treatment for xperimental autoimmune uveoretinitis","volume":"41","author":"Ikeda","year":"1997","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib28","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0002-9394(14)76692-9","article-title":"Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis","volume":"112","author":"Nussenblatt","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib29","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/bjo.81.12.1107","article-title":"Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporine A","volume":"81","author":"Dick","year":"1997","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib30","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00012","article-title":"Use of cytotoxic agents and cyclospoorine in the treatment of autoimmune disease. Part 1: rheumatologic and renal disease","volume":"128","author":"Langford","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2010.05.017_bib31","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/bjo.82.7.737","article-title":"Cyclosporin A therapy in refractory non-infectious childhood uveitis","volume":"82","author":"Kilmartin","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib32","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s003470050070","article-title":"Cyclosporin A in therapy of chronic uveitis in childhood","volume":"93","author":"Schlote","year":"1996","journal-title":"Ophthalmologe"},{"key":"10.1016\/j.autrev.2010.05.017_bib33","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/S0161-6420(98)91120-4","article-title":"Cyclosporine therapy for severe sight threatening uveitis in children and adolescents","volume":"105","author":"Walton","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2010.05.017_bib34","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/00055735-200312000-00013","article-title":"Diagnosis and treatment of juvenile idiopathic arthritis-associated uveitis","volume":"14","author":"Foster","year":"2003","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib35","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/rheumatology\/40.8.907","article-title":"Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study","volume":"40","author":"Gerloni","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2010.05.017_bib36","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jbspin.2008.10.015","article-title":"Ocular threat in juvenile idiopathic arthritis","volume":"76","author":"Marvillet","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2010.05.017_bib37","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/eye.2008.174","article-title":"Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis","volume":"23","author":"Tappeiner","year":"2009","journal-title":"Eye"},{"key":"10.1016\/j.autrev.2010.05.017_bib38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4103\/0301-4738.58472","article-title":"Low-dose cyclosporine treatment for sight-threatening uveitis: efficacy, toxicity, and tolerance","volume":"58","author":"Mathews","year":"2010","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib39","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1056\/NEJM199206183262502","article-title":"Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases","volume":"326","author":"Feutren","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2010.05.017_bib40","first-page":"68","article-title":"Dosage of cyclosporin A in children with retinal transplants","volume":"22","author":"Hoyer","year":"1984","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.autrev.2010.05.017_bib41","first-page":"349","article-title":"Nephrotoxicity and hypertension in patients with autoimmune disease treated with cyclosporine","volume":"20","author":"Dieterle","year":"1988","journal-title":"Transplant Proc"},{"key":"10.1016\/j.autrev.2010.05.017_bib42","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1001\/archopht.123.5.634","article-title":"Cyclosporine vs. tacrolimus therapy for posterior intermediate uveitis","volume":"123","author":"Murphy","year":"2005","journal-title":"Arch Ophtalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib43","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ophtha.2007.01.026","article-title":"Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis","volume":"114","author":"Hogan","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2010.05.017_bib44","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1006\/cimm.1994.1193","article-title":"Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin","volume":"156","author":"Aagard-Tillery","year":"1994","journal-title":"Cell Immunol"},{"key":"10.1016\/j.autrev.2010.05.017_bib45","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/bjo.2004.048199","article-title":"The efficacy of sirolimus in the treatment of patients with refractory uveitis","volume":"89","author":"Shanmuganathan","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib46","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ophtha.2009.06.060","article-title":"Cyclophosphamide for ocular inflammatory disease","volume":"117","author":"Pujari","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2010.05.017_bib47","first-page":"141","article-title":"Chlorambucil in the treatment of iridocyclitis in juvenile rheumatoid arthritis","volume":"8","author":"Mehra","year":"1981","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2010.05.017_bib48","first-page":"967","article-title":"Chlorambucil in the treatment of intractable uveitis associated with juvenile chronic arthritis","volume":"12","author":"Palmer","year":"1985","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2010.05.017_bib49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0161-6420(01)00864-8","article-title":"Efficacy and safety of chlorambucil in intractable noninfectious uveitis. The Massachusetts eye and ear infirmary experience","volume":"109","author":"Miserocchi","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2010.05.017_bib50","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000055677","article-title":"Aqueous humor and serum tumor necrosis factor alpha in clinical uveitis","volume":"33","author":"Santos Lacomba","year":"2001","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.autrev.2010.05.017_bib51","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.autrev.2007.03.003","article-title":"Biological and clinical effects of anti-TNFalpha treatment","volume":"7","author":"Valesini","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2010.05.017_bib52","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1167\/iovs.03-0659","article-title":"Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation","volume":"45","author":"Greiner","year":"2004","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.autrev.2010.05.017_bib53","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1006\/jaut.1998.0197","article-title":"Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis","volume":"11","author":"Dick","year":"1998","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2010.05.017_bib54","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1136\/bjo.2006.108050","article-title":"Adalimumab in the therapy of uveitis in childhood","volume":"91","author":"Mansour","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib55","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ajo.2007.08.018","article-title":"Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up","volume":"144","author":"Ardoin","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib56","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/ard.2006.058248","article-title":"Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis","volume":"66","author":"Tynj\u00e4l\u00e4","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2010.05.017_bib57","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/ICU.0b013e3282f03d42","article-title":"Biologics in the treatment of uveitis","volume":"18","author":"Imrie","year":"2007","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib58","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/eye.2009.203","article-title":"Switching biologic agents for uveitis","volume":"23","author":"Dhingra","year":"2009","journal-title":"Eye"},{"key":"10.1016\/j.autrev.2010.05.017_bib59","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/bjo.2006.103721","article-title":"Adalimumab in the therapy of uveitis in childhood","volume":"91","author":"Biester","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib60","first-page":"1","article-title":"New treatment approaches in juvenile idiopathic arthritis","volume":"7","author":"Holzinger","year":"2009","journal-title":"Int J Adv Rheumatol"},{"key":"10.1016\/j.autrev.2010.05.017_bib61","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2004.08.004","article-title":"Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review","volume":"4","author":"Atzeni","year":"2005","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2010.05.017_bib62","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ophtha.2006.01.005","article-title":"Favorable response to high-dose infliximab for refractory childhood uveitis","volume":"113","author":"Kahn","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2010.05.017_bib63","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/ICU.0b013e3283126d20","article-title":"Chee SP immunosuppressive therapy for ocular diseases","volume":"19","author":"Jap","year":"2008","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib64","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1442-9071.2005.01062.x","article-title":"Manners P infliximab for juvenile idiopathic arthritis-associated uveitis","volume":"33","author":"Richards","year":"2005","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib65","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/rheumatology\/kel030","article-title":"Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis","volume":"45","author":"Saurenmann","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2010.05.017_bib66","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ophtha.2005.09.037","article-title":"Retrospective case review of pediatric patients with uveitis treated with infliximab","volume":"113","author":"Rajaraman","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2010.05.017_bib67","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ajo.2007.08.018","article-title":"Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up","volume":"144","author":"Ardoin","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib68","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/rheumatology\/ken298","article-title":"Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis","volume":"47","author":"Simonini","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2010.05.017_bib69","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jaapos.2008.08.007","article-title":"Retrospective analysis of children with uveitis treated with infliximab","volume":"12","author":"Tugal-Tutkun","year":"2008","journal-title":"J AAPOS"},{"key":"10.1016\/j.autrev.2010.05.017_bib70","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2010.05.017_bib71","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O","article-title":"Etanercept therapy in children with treatment-resistant uveitis","volume":"44","author":"Reiff","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.05.017_bib72","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1002\/art.11155","article-title":"Long-term outcome of etanercept therapy in children with treatment-refractory uveitis","volume":"48","author":"Reiff","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.05.017_bib73","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/art.20904","article-title":"A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"53","author":"Smith","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.05.017_bib74","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/rheumatology\/keh658","article-title":"Etanercept and uveitis in patients with juvenile idiopathic arthritis","volume":"44","author":"Schmeling","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2010.05.017_bib75","first-page":"572.575","article-title":"Adalimumab therapy for childhood uveitis","volume":"149","author":"Vazquez Cobain","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.autrev.2010.05.017_bib76","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.autrev.2005.09.011","article-title":"Juvenile idiopathic arthritis","volume":"5","author":"Borchers","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2010.05.017_bib77","doi-asserted-by":"crossref","first-page":"188-93","DOI":"10.1016\/j.autrev.2009.10.003","article-title":"Autoimmune diseases induced by biological agents: a double-edged sword?","volume":"9","author":"Ramos-Casals","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2010.05.017_bib78","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/RHU.0b013e31813c0e36","article-title":"Pediatric rheumatology for the adult rheumatologist II: uveitis in juvenile idiopathic arthritis","volume":"13","author":"Wright","year":"2007","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2010.05.017_bib79","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/rheumatology\/kem356","article-title":"Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis","volume":"47","author":"Tynj\u00e4l\u00e4","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2010.05.017_bib80","first-page":"S10","article-title":"Comparison between infliximab and adalimumab for the treatment of refractory chronic uveitis in childhood","volume":"60","author":"Simonini","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.05.017_bib81","doi-asserted-by":"crossref","first-page":"452","DOI":"10.4049\/jimmunol.158.1.452","article-title":"Humanized antibody against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases","volume":"158","author":"Guex-Croiser","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2010.05.017_bib82","first-page":"7462","article-title":"Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I\/II clinical trial","volume":"96","author":"Nussenblat","year":"1999","journal-title":"Med Sci"},{"key":"10.1016\/j.autrev.2010.05.017_bib83","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0161-6420(02)01932-2","article-title":"Treatment of ocular inflammatory disorders with daclizumab","volume":"110","author":"Papaliodis","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2010.05.017_bib84","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/bjo.2007.124081","article-title":"Biological response modifier therapy for refractory childhood uveitis","volume":"91","author":"Gallagher","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib85","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.ajo.2009.06.003","article-title":"High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis","volume":"148","author":"Sen","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib86","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jaut.2004.11.006","article-title":"SOCS5 mRNA levels in peripheral blood mononuclear cells (PBMC): a potential bio-marker for monitoring response of uveitis patients to daclizumab therapy","volume":"24","author":"Egwuagu","year":"2005","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2010.05.017_bib87","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaut.2008.05.001","article-title":"High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis","volume":"31","author":"Yeh","year":"2008","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2010.05.017_bib88","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2010.05.017_bib89","first-page":"1897","article-title":"Abatacept for refractory juvenile idiopathic arthritis-associated uveitis\u2014a case report","volume":"35","author":"Angeles-Han","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2010.05.017_bib90","unstructured":"Zulian F., Balzarin M., Falcini F., Alessio M., Cimaz R., et al. Abatacept in refractory anti-TNF resistant juvenile idiopathic arthritis-related uveitis. Arthritis Care Res 2010 (in press) doi 10.1002\/acr.20115."},{"key":"10.1016\/j.autrev.2010.05.017_bib91","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/bjo.72.2.83","article-title":"Activated T lymphocytes in uveitis","volume":"72","author":"Deschenes","year":"1988","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib92","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3109\/02713689509003752","article-title":"Two-color flow cytometric analysis of activated T lymphocytes in aqueous humor of patients with endogenous vs. exogenous uveitis","volume":"14","author":"Wang","year":"1995","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.autrev.2010.05.017_bib93","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/01.icu.0000177414.79030.32","article-title":"Management of chronic pediatric uveitis","volume":"16","author":"Levy-Clarke","year":"2005","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.autrev.2010.05.017_bib94","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/00148581-200911040-00002","article-title":"Non-infectious pediatric uveitis: an update on immunomodulatory management","volume":"11","author":"Sharma","year":"2009","journal-title":"Paediatr Drugs"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899721000100X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899721000100X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T09:25:57Z","timestamp":1685611557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899721000100X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":94,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S156899721000100X"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2010.05.017","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}